Medigene reports Phase I/II data for prostate cancer vaccine

Medigene AG (Xetra:MDG1) said none of five high-risk prostate cancer patients who underwent radical surgery experienced biochemical relapse following vaccination with its DC vaccine targeting prostate-specific antigen (PSA; KLK3) that was generated with a toll-like receptor 7 (TLR7)/TLR8 ligand-containing maturation cocktail. The company said three of 15 patients in the trial who received the vaccine generated with the standard protocol maturation cocktail, which included GM-CSF and IL-4, experienced biochemical relapse. Data were presented at the American Association for Cancer Research meeting in Chicago...